Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Purpose
This phase II trial studies nivolumab and ipilimumab in treating patients with rare tumors. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial enrolls participants for the following cohorts based on condition: 1. Epithelial tumors of nasal cavity, sinuses, nasopharynx: A) Squamous cell carcinoma with variants of nasal cavity, sinuses, and nasopharynx and trachea (excluding laryngeal, nasopharyngeal cancer [NPC], and squamous cell carcinoma of the head and neck [SCCHN]) B) Adenocarcinoma and variants of nasal cavity, sinuses, and nasopharynx (closed to accrual 07/27/2018) 2. Epithelial tumors of major salivary glands (closed to accrual 03/20/2018) 3. Salivary gland type tumors of head and neck, lip, esophagus, stomach, trachea and lung, breast and other location (closed to accrual) 4. Undifferentiated carcinoma of gastrointestinal (GI) tract 5. Adenocarcinoma with variants of small intestine (closed to accrual 05/10/2018) 6. Squamous cell carcinoma with variants of GI tract (stomach small intestine, colon, rectum, pancreas) (closed to accrual 10/17/2018) 7. Fibromixoma and low grade mucinous adenocarcinoma (pseudomixoma peritonei) of the appendix and ovary (closed to accrual 03/20/2018) 8. Rare pancreatic tumors including acinar cell carcinoma, mucinous cystadenocarcinoma or serous cystadenocarcinoma. Pancreatic adenocarcinoma is not eligible 9. Intrahepatic cholangiocarcinoma (closed to accrual 03/20/2018) 10. Extrahepatic cholangiocarcinoma and bile duct tumors (closed to accrual 03/20/2018) 11. Sarcomatoid carcinoma of lung 12. Bronchoalveolar carcinoma lung. This condition is now also referred to as adenocarcinoma in situ, minimally invasive adenocarcinoma, lepidic predominant adenocarcinoma, or invasive mucinous adenocarcinoma 13. Non-epithelial tumors of the ovary: A) Germ cell tumor of ovary B) Mullerian mixed tumor and adenosarcoma (closed to accrual 03/30/2018) 14. Trophoblastic tumor: A) Choriocarcinoma (closed to accrual 04/15/2019) 15. Transitional cell carcinoma other than that of the renal, pelvis, ureter, or bladder (closed to accrual 04/15/2019) 16. Cell tumor of the testes and extragonadal germ tumors: A) Seminoma and testicular sex cord cancer B) Non seminomatous tumor C) Teratoma with malignant transformation (closed to accrual 3/15/2019) 17. Epithelial tumors of penis - squamous adenocarcinoma cell carcinoma with variants of penis 18. Squamous cell carcinoma variants of the genitourinary (GU) system 19. Spindle cell carcinoma of kidney, pelvis, ureter 20. Adenocarcinoma with variants of GU system (excluding prostate cancer) (closed to accrual 07/27/2018) 21. Odontogenic malignant tumors 22. Pancreatic neuroendocrine tumor (PNET) (formerly named: Endocrine carcinoma of pancreas and digestive tract.) 23. Neuroendocrine carcinoma including carcinoid of the lung (closed to accrual 12/19/2017) 24. Pheochromocytoma, malignant 25. Paraganglioma (closed to accrual 11/29/2018) 26. Carcinomas of pituitary gland, thyroid gland parathyroid gland and adrenal cortex 27. Desmoid tumors 28. Peripheral nerve sheath tumors and NF1-related tumors (closed to accrual 09/19/2018) 29. Malignant giant cell tumors 30. Chordoma (closed to accrual 11/29/2018) 31. Adrenal cortical tumors (closed to accrual 06/27/2018) 32. Tumor of unknown primary (Cancer of Unknown Primary; CuP) (closed to accrual 12/22/2017) 33. Not Otherwise Categorized (NOC) Rare Tumors [To obtain permission to enroll in the NOC cohort, contact: S1609SC@swog.org] (closed to accrual 03/15/2019) 34. Adenoid cystic carcinoma (closed to accrual 02/06/2018) 35. Vulvar cancer 36. MetaPLASTIC carcinoma (of the breast) 37. Gastrointestinal stromal tumor (GIST) (closed to accrual 09/26/2018) 38. Perivascular epithelioid cell tumor (PEComa) 39. Apocrine tumors/extramammary Paget's disease 40. Peritoneal mesothelioma 41. Basal cell carcinoma 42. Clear cell cervical cancer 43. Esthenioneuroblastoma 44. Endometrial carcinosarcoma (malignant mixed Mullerian tumors) (closed to accrual) 45. Clear cell cervical endometrial cancer 46. Clear cell ovarian cancer 47. Gestational trophoblastic disease (GTD) 48. Gallbladder cancer 49. Small cell carcinoma of the ovary, hypercalcemic type 50. PD-L1 amplified tumors 51. Angiosarcoma 52. High-grade neuroendocrine carcinoma (pancreatic neuroendocrine tumor [PNET] should be enrolled in Cohort 22; prostatic neuroendocrine carcinomas should be enrolled into Cohort 53). Small cell lung cancer is not eligible 53. Treatment-emergent small-cell neuroendocrine prostate cancer (t-SCNC)
Conditions
- Acinar Cell Carcinoma
- Adenoid Cystic Carcinoma
- Adrenal Cortex Carcinoma
- Adrenal Gland Pheochromocytoma
- Anal Canal Neuroendocrine Carcinoma
- Anal Canal Undifferentiated Carcinoma
- Angiosarcoma
- Apocrine Neoplasm
- Appendix Mucinous Adenocarcinoma
- Bartholin Gland Transitional Cell Carcinoma
- Basal Cell Carcinoma
- Bladder Adenocarcinoma
- Cervical Adenocarcinoma
- Cervical Clear Cell Adenocarcinoma
- Cholangiocarcinoma
- Chordoma
- Colorectal Squamous Cell Carcinoma
- Desmoid-Type Fibromatosis
- Endometrial Transitional Cell Carcinoma
- Endometrioid Adenocarcinoma
- Esophageal Neuroendocrine Carcinoma
- Esophageal Undifferentiated Carcinoma
- Extrahepatic Bile Duct Carcinoma
- Extramammary Paget Disease
- Fallopian Tube Adenocarcinoma
- Fallopian Tube Transitional Cell Carcinoma
- Fibromyxoid Tumor
- Gallbladder Carcinoma
- Gastric Neuroendocrine Carcinoma
- Gastric Squamous Cell Carcinoma
- Gastric Undifferentiated Carcinoma
- Gastrointestinal Stromal Tumor
- Gestational Trophoblastic Tumor
- Giant Cell Carcinoma
- Intestinal Neuroendocrine Carcinoma
- Intrahepatic Cholangiocarcinoma
- Lung Carcinoid Tumor
- Lung Sarcomatoid Carcinoma
- Major Salivary Gland Carcinoma
- Malignant Odontogenic Neoplasm
- Malignant Peripheral Nerve Sheath Tumor
- Malignant Testicular Sex Cord-Stromal Tumor
- Metaplastic Breast Carcinoma
- Metastatic Malignant Neoplasm of Unknown Primary
- Minimally Invasive Lung Adenocarcinoma
- Mixed Mesodermal (Mullerian) Tumor
- Mucinous Adenocarcinoma
- Mucinous Cystadenocarcinoma
- Nasal Cavity Adenocarcinoma
- Nasal Cavity Carcinoma
- Nasopharyngeal Carcinoma
- Nasopharyngeal Papillary Adenocarcinoma
- Nasopharyngeal Undifferentiated Carcinoma
- Oral Cavity Carcinoma
- Oropharyngeal Undifferentiated Carcinoma
- Ovarian Adenocarcinoma
- Ovarian Clear Cell Adenocarcinoma
- Ovarian Germ Cell Tumor
- Ovarian Mucinous Adenocarcinoma
- Ovarian Squamous Cell Carcinoma
- Ovarian Transitional Cell Carcinoma
- Pancreatic Acinar Cell Carcinoma
- Pancreatic Neuroendocrine Carcinoma
- Paraganglioma
- Paranasal Sinus Adenocarcinoma
- Paranasal Sinus Carcinoma
- Parathyroid Gland Carcinoma
- PEComa
- Peritoneal Mesothelioma
- Pituitary Gland Carcinoma
- Placental Choriocarcinoma
- Primary Peritoneal High Grade Serous Adenocarcinoma
- Pseudomyxoma Peritonei
- Rare Disorder
- Scrotal Squamous Cell Carcinoma
- Seminal Vesicle Adenocarcinoma
- Seminoma
- Serous Cystadenocarcinoma
- Small Intestinal Adenocarcinoma
- Small Intestinal Squamous Cell Carcinoma
- Solid Neoplasm
- Spindle Cell Neoplasm
- Squamous Cell Carcinoma of the Penis
- Teratoma With Somatic-Type Malignancy
- Testicular Non-Seminomatous Germ Cell Tumor
- Thyroid Gland Carcinoma
- Tracheal Carcinoma
- Transitional Cell Carcinoma
- Ureter Adenocarcinoma
- Ureter Squamous Cell Carcinoma
- Urethral Adenocarcinoma
- Urethral Squamous Cell Carcinoma
- Vaginal Adenocarcinoma
- Vaginal Squamous Cell Carcinoma, Not Otherwise Specified
- Vulvar Carcinoma
Eligibility
- Eligible Ages
- Over 18 Years
- Eligible Genders
- All
- Accepts Healthy Volunteers
- No
Criteria
Inclusion Criteria:
- Patients are eligible under ONE of the following criteria:
- For all cohorts except the gestational trophoblastic disease (GTD) (Cohort #47),
patients must have histologically and/or biochemically confirmed rare cancer and
must be able to submit specimens. To be eligible for the GTD cohort: patients
must have disease confirmed by quantitative serum beta-human chorionic
gonadotropin (hCG) within 28 days prior to registration and must be able to
submit blood specimens (tissue submission is not required for patients who will
be registered to the GTD cohort [Cohort #47]); NOTE: Subsequent to site's
Institutional Review Board (IRB) approval of revision 3, patients are NOT
required to participate in EAY131 "National Cancer Institute (NCI)-Molecular
Analysis for Therapy Choice (MATCH)" to register to S1609 OR
- FOR PATIENTS WITH PD-L1 AMPLIFICATION ONLY: All solid tumors (excluding lymphoma)
are allowed for the PD-L1 amplified cohort if they have PD-L1 amplification;
PD-L1 amplification is defined as having deoxyribonucleic acid (DNA) copy number
of equal to or greater than six by any of the following Clinical Laboratory
Improvement Act (CLIA)-approved next generation sequencing (NGS) tests:
Foundation Medicine, Caris, MSK Impact, MD Anderson, Tempus, or Neogenomics;
(fluorescence in situ hybridization [FISH] is not allowed); the assay must be
done at or after the diagnosis of advanced disease, but PRIOR TO REGISTRATION OR
- FOR PATIENTS ENROLLED IN EAY131 "NCI-MATCH" PRIOR TO EAY131 ADDENDUM 10 ONLY:
Patients must have histologically confirmed rare cancer that did not have a match
to a molecularly-guided therapy on EAY131 "NCI-MATCH" protocol or who are off
protocol treatment on EAY131, "NCI-MATCH" and have no further molecularly-matched
treatment recommendations per EAY131, "NCI-MATCH" or who are otherwise unable to
receive EAY131, "NCI-MATCH" therapy
- Patients who do not qualify for one of the histologic cohorts and are not on the
ineligible histology list may be considered for registration in the "Not Otherwise
Categorized" Rare Tumors cohort with confirmation of at least one of the study chairs
via email
- NOTE: The "Not Otherwise Categorized" Rare Tumors cohort was permanently closed
to accrual on 3/15/2019
- Patients who are determined to have a rare cancer with unknown primary site are
eligible under cohort #32 (tumor of unknown primary [cancer of unknown primary; CuP]),
provided that there is histologic documentation of metastatic malignancy with no
discernible primary site identified from histopathologic review, physical exam and
associated cross-sectional imaging of the chest, abdomen, and pelvis
- NOTE: The "Tumor of unknown primary (Cancer of Unknown Primary; CuP" cohort was
permanently closed to accrual on 12/22/2017
- Patients must also meet one of the following:
- Patients must have progressed following at least one line of standard systemic
therapy and there must not be other approved/standard therapy available that has
been shown to prolong overall survival (i.e. in a randomized trial against
another standard treatment or by comparison to historical controls); patients who
cannot receive other standard therapy that has been shown to prolonged survival
due to medical issues will be eligible, if other eligibility criteria are met; OR
- Patients for whose disease no standard treatment exists that has been shown to
prolong overall survival
- For all cohorts except the GTD cohort (Cohort #47): Patients must have a diagnostic
quality computed tomography (CT) scan or magnetic resonance imaging (MRI), performed
within 28 days prior to registration, which demonstrates measurable disease, as
defined in RECIST v. 1.1; scans must include imaging of the chest, abdomen and pelvis,
with the exception of patients with head/neck cancer, who must have imaging of the
chest, abdomen, pelvis and neck; if there is clinical suspicion for bone metastases at
the time of enrollment (in the judgement of the treating investigator) bone scan
should be performed; bone scans done within 42 days prior to registration may be used
to establish baseline condition at registration
- No other prior malignancy is allowed except for the following:
- Adequately managed stage I or II cancer from which the patient is currently in
complete remission
- Any other cancer from which the patient has been disease free for one year
- Adequately managed stage I or II follicular thyroid or prostate cancer is also
eligible, wherein patient is not required to be in complete remission
- Note: Second primary tumors are not allowed concurrent with any of the eligible
rare cancers
- For all cohorts except the PD-L1 amplified tumors cohort (Cohort # 50): Patients may
have received either prior anti-CTLA4 or other prior anti-PD-1/anti-PD-L1 therapy, but
not both, provided that it is completed >= 4 weeks prior to registration. To be
eligible for the PD-L1 amplified tumors cohort (Cohort #50): Patients must not have
received anti-PD-1/anti-PD-L1 therapy; prior anti-CTLA-4 is allowed provided that it
is completed >= 4 weeks prior to registration
- Patients who had prior grade 3 or higher immune-related adverse event (e.g.
pneumonitis, hepatitis, colitis, endocrinopathy) with prior immunotherapy (e.g. cancer
vaccine, cytokine, etc.) are not eligible
- Patients with clinically controlled thyroiditis or pituitary disorders on stable
replacement therapy are eligible
- Patients are not eligible if they have had or are planned for solid organ transplant
- Patients with autoimmune disease who are otherwise eligible must not have received
steroid and immunosuppressive therapy within 28 days prior to registration
- Patients with brain metastases or primary brain tumors must have completed treatment,
surgery or radiation therapy >= 28 days prior to registration and have stable disease
at time of registration; these patients must also have a CT or MRI of the brain to
evaluate for CNS disease within 42 days prior to registration to S1609; metastatic
brain parenchymal disease must have been treated and patient must be off steroids for
7 days prior to registration
- Patients must not currently be receiving any other investigational agents or any other
systemic anti-cancer therapy (including radiation, excluding RANKL inhibitors and
bisphosphonates); in event patient recently received any other systemic anti-cancer
therapy, patient must be off therapy at least 7 days prior to registration and any
therapy-induced toxicity must have recovered to =< grade 1, except alopecia and =<
grade 2 neuropathy which are allowed; any planned radiation therapy must be completed
before registration to S1609
- Patients must not have prior history of allergy or known hypersensitivity to nivolumab
or ipilimumab
- Hormonal or endocrine blockade is permitted as long as patient has demonstrated
progression on prior therapy (e.g. gonadotrophin releasing hormone [GnRH],
somatostatin); long-acting somatostatin analogs (including octreotide) and androgen
deprivation treatment (including long-acting leuprolide) are permitted while on
protocol therapy
- Patients must have a Zubrod performance status of 0-2
- Absolute neutrophil count (ANC) >= 1,000/mcL (within 28 days prior to registration)
- Platelets >= 75,000/mcL (within 28 days prior to registration)
- Hemoglobin >= 8 g/dL (within 28 days prior to registration)
- Total bilirubin =< 2.0 x institutional upper limit of normal (IULN) or for
documented/suspected Gilbert's disease, total bilirubin =< 3.0 x IULN (within 28 days
prior to registration)
- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) both =< 3 x IULN
(within 28 days prior to registration)
- Serum creatinine =< 2.0 x IULN (within 28 days prior to registration)
- Creatinine clearance (CrCl) >= 50 mL/min., as estimated by the Cockcroft and Gault
formula; estimated creatinine clearance is based on actual body weight (within 28 days
prior to registration)
- Patients must have adequate thyroid function, as evidenced by either
thyroid-stimulating hormone (TSH) or, free thyroxine (T4) serum tests demonstrating
values within the normal range, within 28 days prior to registration; Note: TSH, with
reflex T4 is allowable if per institutional standard; patients who have undergone
thyroidectomy or who are on thyroid suppression for their cancer are not required to
have normal TSH and free T4
- Patients must have adequate adrenal axis function, as evidenced by adrenocorticotropic
hormone (ACTH) values within the institutional normal ranges OR cortisol levels within
institutional normal ranges (ante meridiem [AM] cortisol preferred), within 28 days
prior to registration; Note: ACTH and cortisol levels are not required for patients
with primary adrenal tumors (e.g. adrenocortical carcinoma)
- For women of childbearing potential, the local investigator must rule out pregnancy;
Except for Cohorts 13 and 47, where tumor types may express beta-hCG, women of
childbearing potential must have a serum or urine pregnancy test within 7 days prior
to registration; for Cohorts 13 and 47, where tumor types may produce hCG (e.g. germ
cell tumors or trophoblastic disease), other pregnancy exclusion methods should be
used to rule out pregnancy, such as ultrasound examination, documented history of
effective contraception, or documented infertility; all females of childbearing
potential must have been demonstrated not to be pregnant within 7 days prior to
registration and agree to use birth control throughout study and for 23 weeks after
completion of protocol therapy; patients must not be pregnant or nursing due to risk
of fetal or nursing infant harm; women of childbearing potential must have agreed to
use an effective contraceptive method; a woman is considered to be of "childbearing
potential" if she has had menses at any time in the preceding 12 consecutive months;
in addition to routine contraceptive methods, "effective contraception" also includes
heterosexual celibacy and surgery intended to prevent pregnancy (or with a side-effect
of pregnancy prevention) defined as a hysterectomy, bilateral oophorectomy or
bilateral tubal ligation; however, if at any point a previously celibate patient
chooses to become heterosexually active during the time period for use of
contraceptive measures outlined in the protocol, she is responsible for beginning
contraceptive measures
- Men of reproductive potential must have agreed to use birth control throughout the
study and for 31 weeks after completion of protocol therapy; in addition to routine
contraceptive methods, "effective contraception" also includes heterosexual celibacy
and surgery intended to prevent pregnancy (vasectomy); however, if at any point a
previously celibate patient chooses to become heterosexually active during the time
period for use of contraceptive measures outlined in the protocol, he is responsible
for beginning contraceptive measures
- Patients must not have known active hepatitis B virus (HBV) or hepatitis virus (HCV)
infection at time of registration; patients with HBV or HCV that have an undetectable
viral load, or in the opinion of the treating investigator is well-controlled, are
eligible
- Patients who are known to be human immunodeficiency virus (HIV)-positive at
registration are eligible at the time of registration:
- CD4+ cell count greater or equal to 250 cells/mm^3
- No history of non-malignancy acquired immunodeficiency syndrome (AIDS)-defining
conditions other than historical low CD4+ cell counts
- Patients must not have active autoimmune disease that has required systemic treatment
in past 2 years (i.e., with use of disease modifying agents, immunosuppressive drugs,
or corticosteroids with doses higher than prednisone 10 mg or equivalent); replacement
therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy
for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic
treatment; autoimmune diseases include but are not limited to autoimmune hepatitis,
inflammatory bowel disease (including ulcerative colitis and Chron's disease), as well
as symptomatic disease (e.g. rheumatoid arthritis, systemic progressive sclerosis
[scleroderma], systemic lupus erythematosus, autoimmune vasculitis [e.g., Wegener's
Granulomatosis]); CNS or motor neuropathy considered of autoimmune origin (e.g.,
Guillain-Barre syndrome and myasthenia gravis, multiple sclerosis or
glomerulonephritis); vitiligo, alopecia, hypothyroidism on stable doses of thyroid
replacement therapy, psoriasis not requiring systemic therapy within the past 2 years
is permitted; short-term steroid premedication for contrast allergy is permitted
- Patients must not have any uncontrolled intercurrent illness including (not limited
to): symptomatic congestive heart failure (CHF) (New York Heart Association [NYHA]
III/IV), unstable angina pectoris or coronary angioplasty, or stenting within 24 weeks
prior to registration, unstable cardiac arrhythmia (ongoing cardiac dysrhythmias of
NCI Common Terminology Criteria for Adverse Events [CTCAE] version [v] 4 grade >= 2),
known psychiatric illness that would limit study compliance, intra-cardiac
defibrillators, known cardiac metastases, or abnormal cardiac valve morphology (>=
grade 3)
- Note: Patients with history of CHF or patients who are deemed at risk because of
underlying cardiovascular disease or exposure to cardiotoxic drugs should have an
electrocardiogram (EKG) and echocardiogram (ECHO), as clinically indicated, at
baseline and at the start of each cycle; patients who have evidence at baseline
(or subsequently) of CHF, myocardial infarction (MI), cardiomyopathy, or myositis
cardiac evaluation (NYHA I/II) should have additional consult by a cardiologist,
including review of EKG, creatine phosphokinase (CPK), troponin, echocardiogram,
as clinically indicated
- Patients must have amylase or lipase within =< 1.5 x IULN without symptoms of
pancreatitis at registration, within 28 days prior to registration
- Patients must not have symptomatic interstitial lung disease or pneumonitis
- Patients must have fully recovered from any adverse effects of major surgery (to =<
grade 1) at least 14 days prior to registration
Study Design
- Phase
- Phase 2
- Study Type
- Interventional
- Allocation
- Non-Randomized
- Intervention Model
- Parallel Assignment
- Primary Purpose
- Treatment
- Masking
- None (Open Label)
Arm Groups
| Arm | Description | Assigned Intervention |
|---|---|---|
|
Experimental Arm I (nivolumab, ipilimumab) |
Patients receive nivolumab IV over 30 minutes on days 1, 15, and 29 and ipilimumab IV over 60 minutes on day 1. Cycles repeat every 42 days in the absence of disease progression or unacceptable toxicity. |
|
|
Experimental Arm II (nivolumab) |
Patients receive nivolumab IV over 30 minutes on days 1, 15 and 29. Cycles repeat every 42 days in the absence of disease progression or unacceptable toxicity. |
|
Recruiting Locations
Birmingham, Alabama 35233
Mobile, Alabama 36688
Anchorage, Alaska 98508
Anchorage, Alaska 99504
Anchorage, Alaska 99508
Anchorage, Alaska 99508
Anchorage, Alaska 99508
Anchorage, Alaska 99508
Anchorage, Alaska 99508
Anchorage, Alaska 99508
Fairbanks, Alaska 99701
Kingman, Arizona 86401
Phoenix, Arizona 85004
Site Public Contact
602-406-8222
Fort Smith, Arkansas 72903
Site Public Contact
800-378-9373
Hot Springs, Arkansas 71913
Jonesboro, Arkansas 72401
Little Rock, Arkansas 72205
Site Public Contact
501-686-8274
Anaheim, California 92806
Antioch, California 94531
Arroyo Grande, California 93420
Auburn, California 95602
Auburn, California 95603
Bakersfield, California 93301
Site Public Contact
661-323-4673
Baldwin Park, California 91706
Bellflower, California 90706
Berkeley, California 94704
Burbank, California 91505
Burlingame, California 94010
Cameron Park, California 95682
Castro Valley, California 94546
Costa Mesa, California 92627
Site Public Contact
877-827-8839
Davis, California 95616
Duarte, California 91010
Dublin, California 94568
Site Public Contact
925-875-1677
Dublin, California 94568
Site Public Contact
877-642-4691
Emeryville, California 94608
Site Public Contact
510-835-9900
Emeryville, California 94608
Site Public Contact
510-629-6682
Fontana, California 92335
Fremont, California 94538
Fremont, California 94538
Fresno, California 93720
Harbor City, California 90710
Irvine, California 92618
La Jolla, California 92093
Loma Linda, California 92354
Site Public Contact
909-558-3375
Los Angeles, California 90027
Los Angeles, California 90033
Site Public Contact
323-865-0451
Los Angeles, California 90033
Site Public Contact
323-865-0451
Los Angeles, California 90034
Los Angeles, California 90048
Site Public Contact
310-423-8965
Martinez, California 94553-3156
Site Public Contact
925-957-5400
Marysville, California 95901
Site Public Contact
530-749-4400
Merced, California 95340
Site Public Contact
209-564-3600
Modesto, California 95355
Modesto, California 95356
Mountain View, California 94040
Mountain View, California 94040
Newport Beach, California 92663
Site Public Contact
323-865-0451
Novato, California 94945
Oakland, California 94609
Site Public Contact
510-204-1414
Oakland, California 94609
Oakland, California 94611
Ontario, California 91761
Orange, California 92868
Site Public Contact
714-734-6220
Orange, California 92868
Palo Alto, California 94301
Panorama City, California 91402
Pasadena, California 91105
Site Public Contact
323-865-0451
Redwood City, California 94063
Richmond, California 94801
Riverside, California 92505
Roseville, California 95661
Roseville, California 95661
Roseville, California 95661
Sacramento, California 95814
Sacramento, California 95816
Sacramento, California 95817
Site Public Contact
916-734-3089
Sacramento, California 95823
Sacramento, California 95825
San Diego, California 92108
San Diego, California 92120
San Diego, California 92123
San Francisco, California 94115
San Francisco, California 94115
San Jose, California 95119
San Leandro, California 94577
San Marcos, California 92078
San Rafael, California 94903
San Rafael, California 94903
Santa Clara, California 95051
Santa Cruz, California 95065
Santa Rosa, California 95403
Santa Rosa, California 95403
South San Francisco, California 94080
Stockton, California 95210
Sunnyvale, California 94086
Truckee, California 96161
Site Public Contact
530-582-6450
Vacaville, California 95687
Vacaville, California 95688
Vallejo, California 94589
Vallejo, California 94589
Walnut Creek, California 94596
Walnut Creek, California 94597
Woodland Hills, California 91367
Aurora, Colorado 80012
Aurora, Colorado 80045
Site Public Contact
720-848-0650
Boulder, Colorado 80301
Boulder, Colorado 80304
Colorado Springs, Colorado 80907
Colorado Springs, Colorado 80907
Colorado Springs, Colorado 80909
Site Public Contact
719-365-2406
Colorado Springs, Colorado 80920
Site Public Contact
719-364-6700
Denver, Colorado 80205
Denver, Colorado 80206
Denver, Colorado 80209
Denver, Colorado 80210
Denver, Colorado 80218
Denver, Colorado 80218
Denver, Colorado 80218
Denver, Colorado 80218
Denver, Colorado 80220
Durango, Colorado 81301
Durango, Colorado 81301
Englewood, Colorado 80113
Englewood, Colorado 80113
Fort Collins, Colorado 80524
Site Public Contact
970-297-6150
Glenwood Springs, Colorado 81601
Site Public Contact
970-384-7570
Golden, Colorado 80401
Grand Junction, Colorado 81501
Greeley, Colorado 80631
Lafayette, Colorado 80026
Site Public Contact
303-673-1622
Lafayette, Colorado 80026
Lakewood, Colorado 80228
Littleton, Colorado 80120
Littleton, Colorado 80122
Lone Tree, Colorado 80124
Lone Tree, Colorado 80124
Longmont, Colorado 80501
Longmont, Colorado 80501
Loveland, Colorado 80539
Parker, Colorado 80138
Pueblo, Colorado 81004
Thornton, Colorado 80260
Wheat Ridge, Colorado 80033
Derby, Connecticut 06418
Fairfield, Connecticut 06824
Guilford, Connecticut 06437
Hartford, Connecticut 06105
New Haven, Connecticut 06510
New Haven, Connecticut 06520
North Haven, Connecticut 06473
Stamford, Connecticut 06904
Site Public Contact
203-323-8944
Trumbull, Connecticut 06611
Waterbury, Connecticut 06708
West Haven, Connecticut 06516
Site Public Contact
203-937-3421
Lewes, Delaware 19958
Newark, Delaware 19713
Newark, Delaware 19713
Newark, Delaware 19713
Newark, Delaware 19718
Rehoboth Beach, Delaware 19971
Seaford, Delaware 19973
Wilmington, Delaware 19801
Washington, District of Columbia 20007
Site Public Contact
202-444-2223
Washington, District of Columbia 20016
Aventura, Florida 33180
Gainesville, Florida 32610
Hollywood, Florida 33021
Miami Beach, Florida 33140
Pembroke Pines, Florida 33028
Site Public Contact
954-265-4325
Tampa, Florida 33607
Tampa, Florida 33612
Tampa, Florida 33612
Atlanta, Georgia 30308
Site Public Contact
888-946-7447
Atlanta, Georgia 30322
Site Public Contact
404-778-1868
Atlanta, Georgia 30342
Site Public Contact
404-851-7115
Columbus, Georgia 31904
Decatur, Georgia 30033
Site Public Contact
404-321-6111
Rome, Georgia 30165
Savannah, Georgia 31405
'Aiea, Hawaii 96701
Site Public Contact
808-539-2273
'Aiea, Hawaii 96701
Site Public Contact
808-487-7447
'Aiea, Hawaii 96701
Site Public Contact
808-486-6000
'Aiea, Hawaii 96701
Site Public Contact
808-678-9000
Honolulu, Hawaii 96813
Site Public Contact
808-524-6115
Honolulu, Hawaii 96813
Site Public Contact
808-532-0315
Honolulu, Hawaii 96813
Honolulu, Hawaii 96813
Site Public Contact
808-545-8548
Honolulu, Hawaii 96813
Site Public Contact
808-522-4333
Honolulu, Hawaii 96813
Site Public Contact
808-586-2979
Honolulu, Hawaii 96817
Site Public Contact
808-536-4888
Honolulu, Hawaii 96817
Site Public Contact
808-531-8521
Honolulu, Hawaii 96817
Site Public Contact
808-547-9816
Honolulu, Hawaii 96817
Site Public Contact
808-547-6881
Honolulu, Hawaii 96819
Honolulu, Hawaii 96826
Site Public Contact
808-983-6090
Lihue, Hawaii 96766
Site Public Contact
808-535-7960
Boise, Idaho 83706
Boise, Idaho 83712
Caldwell, Idaho 83605
Coeur d'Alene, Idaho 83814
Emmett, Idaho 83617
Fruitland, Idaho 83619
Meridian, Idaho 83642
Meridian, Idaho 83642
Nampa, Idaho 83686
Nampa, Idaho 83686
Post Falls, Idaho 83854
Sandpoint, Idaho 83864
Twin Falls, Idaho 83301
Aurora, Illinois 60504
Bloomington, Illinois 61704
Canton, Illinois 61520
Carbondale, Illinois 62902
Carterville, Illinois 62918
Carthage, Illinois 62321
Centralia, Illinois 62801
Chicago, Illinois 60608
Chicago, Illinois 60611
Chicago, Illinois 60612
Site Public Contact
312-864-5204
Chicago, Illinois 60612
Chicago, Illinois 60637
Chicago, Illinois 60657
Site Public Contact
773-296-5360
Danville, Illinois 61832
Decatur, Illinois 62526
Decatur, Illinois 62526
Effingham, Illinois 62401
Effingham, Illinois 62401
Eureka, Illinois 61530
Galesburg, Illinois 61401
Galesburg, Illinois 61401
Site Public Contact
309-344-2831
Geneva, Illinois 60134
Harvey, Illinois 60426
Kewanee, Illinois 61443
Lake Forest, Illinois 60045
Macomb, Illinois 61455
Mattoon, Illinois 61938
Maywood, Illinois 60153
Site Public Contact
708-226-4357
Melrose Park, Illinois 60160
Site Public Contact
708-450-4554
Mount Vernon, Illinois 62864
Site Public Contact
618-242-4600
New Lenox, Illinois 60451
Orland Park, Illinois 60462
Ottawa, Illinois 61350
Pekin, Illinois 61554
Pekin, Illinois 61554
Peoria, Illinois 61615
Peoria, Illinois 61615
Peoria, Illinois 61636
Peoria, Illinois 61637
Peru, Illinois 61354
Peru, Illinois 61354
Site Public Contact
815-664-4141
Princeton, Illinois 61356
Springfield, Illinois 62702
Site Public Contact
217-545-7929
Springfield, Illinois 62702
Site Public Contact
800-444-7541
Springfield, Illinois 62781
Site Public Contact
217-788-3528
Swansea, Illinois 62226
Swansea, Illinois 62226
Urbana, Illinois 61801
Urbana, Illinois 61801
Warrenville, Illinois 60555
Yorkville, Illinois 60560
Avon, Indiana 46123
Carmel, Indiana 46032
Evansville, Indiana 47713
Indianapolis, Indiana 46202
Indianapolis, Indiana 46202
Indianapolis, Indiana 46290
Newburgh, Indiana 47630
South Bend, Indiana 46601
Site Public Contact
800-284-7370
Ames, Iowa 50010
Site Public Contact
515-956-4132
Ames, Iowa 50010
Site Public Contact
515-956-4132
Boone, Iowa 50036
Site Public Contact
515-956-4132
Cedar Rapids, Iowa 52403
Site Public Contact
319-365-4673
Cedar Rapids, Iowa 52403
Site Public Contact
319-363-2690
Clive, Iowa 50325
Clive, Iowa 50325
Council Bluffs, Iowa 51503
Des Moines, Iowa 50309
Site Public Contact
515-241-6727
Des Moines, Iowa 50309
Site Public Contact
515-282-2921
Des Moines, Iowa 50314
Site Public Contact
515-282-2200
Des Moines, Iowa 50314
Des Moines, Iowa 50314
Des Moines, Iowa 50316
Site Public Contact
515-241-8704
Fort Dodge, Iowa 50501
Site Public Contact
515-956-4132
Fort Dodge, Iowa 50501
Site Public Contact
515-574-8302
Jefferson, Iowa 50129
Site Public Contact
515-956-4132
Marshalltown, Iowa 50158
Site Public Contact
515-956-4132
West Des Moines, Iowa 50266-7700
Site Public Contact
515-343-1000
West Des Moines, Iowa 50266
Chanute, Kansas 66720
Coffeyville, Kansas 67337
Site Public Contact
620-252-1606
Dodge City, Kansas 67801
El Dorado, Kansas 67042
Fairway, Kansas 66205
Hays, Kansas 67601
Site Public Contact
785-623-5774
Independence, Kansas 67301
Kansas City, Kansas 66112
Kansas City, Kansas 66160
Kingman, Kansas 67068
Liberal, Kansas 67905
Manhattan, Kansas 66502
McPherson, Kansas 67460
Newton, Kansas 67114
Olathe, Kansas 66061
Overland Park, Kansas 66210
Parsons, Kansas 67357
Pittsburg, Kansas 66762
Site Public Contact
620-235-7900
Pratt, Kansas 67124
Salina, Kansas 67401
Salina, Kansas 67401
Topeka, Kansas 66606
Site Public Contact
785-295-8000
Wellington, Kansas 67152
Westwood, Kansas 66205
Wichita, Kansas 67208
Wichita, Kansas 67208
Wichita, Kansas 67214
Wichita, Kansas 67214
Wichita, Kansas 67214
Winfield, Kansas 67156
Bardstown, Kentucky 40004
Corbin, Kentucky 40701
Lexington, Kentucky 40504
Lexington, Kentucky 40509
London, Kentucky 40741
Louisville, Kentucky 40202
Louisville, Kentucky 40215
Louisville, Kentucky 40245
Shepherdsville, Kentucky 40165
Baton Rouge, Louisiana 70806
Site Public Contact
225-381-6451
Baton Rouge, Louisiana 70809
Site Public Contact
225-767-0822
Baton Rouge, Louisiana 70809
Baton Rouge, Louisiana 70816
Baton Rouge, Louisiana 70836
Kenner, Louisiana 70065
Metairie, Louisiana 70006
Metairie, Louisiana 70006
New Orleans, Louisiana 70112
New Orleans, Louisiana 70112
Site Public Contact
504-988-6121
New Orleans, Louisiana 70112
New Orleans, Louisiana 70121
Bangor, Maine 04401
Site Public Contact
207-973-4274
Brewer, Maine 04412
Site Public Contact
800-987-3005
Baltimore, Maryland 21204
Site Public Contact
443-849-3706
Baltimore, Maryland 21287
Bethesda, Maryland 20892
Site Public Contact
800-411-1222
Cumberland, Maryland 21502
Site Public Contact
240-964-1400
Frederick, Maryland 21701
Frederick, Maryland 21702
Site Public Contact
301-668-7043
Springfield, Massachusetts 01104
Site Public Contact
413-748-9234
Springfield, Massachusetts 01199
Adrian, Michigan 49221
Site Public Contact
517-265-0116
Ann Arbor, Michigan 48106
Ann Arbor, Michigan 48109
Site Public Contact
800-865-1125
Battle Creek, Michigan 49017
Brighton, Michigan 48114
Brighton, Michigan 48114
Brownstown, Michigan 48183
Canton, Michigan 48188
Canton, Michigan 48188
Caro, Michigan 48723
Chelsea, Michigan 48118
Chelsea, Michigan 48118
Clarkston, Michigan 48346
Clarkston, Michigan 48346
Clinton Township, Michigan 48038
Dearborn, Michigan 48126
Detroit, Michigan 48202
Detroit, Michigan 48236
East China Township, Michigan 48054
Escanaba, Michigan 49829
Flint, Michigan 48503
Flint, Michigan 48503
Flint, Michigan 48503
Flint, Michigan 48503
Grand Rapids, Michigan 49503
Grand Rapids, Michigan 49503
Grand Rapids, Michigan 49503
Grosse Pointe Woods, Michigan 48236
Grosse Pointe Woods, Michigan 48236
Grosse Pointe Woods, Michigan 48236
Jackson, Michigan 49201
Kalamazoo, Michigan 49007
Kalamazoo, Michigan 49007
Kalamazoo, Michigan 49048
Lansing, Michigan 48912
Livonia, Michigan 48154
Livonia, Michigan 48154
Macomb, Michigan 48044
Macomb, Michigan 48044
Manistique, Michigan 49854
Marlette, Michigan 48453
Monroe, Michigan 48162
Monroe, Michigan 48162
Site Public Contact
800-444-3561
Muskegon, Michigan 49444
Niles, Michigan 49120
Site Public Contact
616-391-1230
Novi, Michigan 48374
Novi, Michigan 48377
Pontiac, Michigan 48341
Pontiac, Michigan 48341
Pontiac, Michigan 48341
Pontiac, Michigan 48341
Port Huron, Michigan 48060
Port Huron, Michigan 48060
Reed City, Michigan 49677
Rochester Hills, Michigan 48309
Saginaw, Michigan 48601
Saginaw, Michigan 48604
Saint Joseph, Michigan 49085
Saint Joseph, Michigan 49085
Southfield, Michigan 48075
Sterling Heights, Michigan 48312
Tawas City, Michigan 48764
Traverse City, Michigan 49684
Warren, Michigan 48088
Warren, Michigan 48093
Warren, Michigan 48093
Warren, Michigan 48093
Warren, Michigan 48093
West Bloomfield, Michigan 48322
West Branch, Michigan 48661
Wyoming, Michigan 49519
Ypsilanti, Michigan 48106
Ypsilanti, Michigan 48197
Bemidji, Minnesota 56601
Brainerd, Minnesota 56401
Burnsville, Minnesota 55337
Cambridge, Minnesota 55008
Coon Rapids, Minnesota 55433
Deer River, Minnesota 56636
Detroit Lakes, Minnesota 56501
Duluth, Minnesota 55805
Duluth, Minnesota 55805
Duluth, Minnesota 55805
Edina, Minnesota 55435
Fergus Falls, Minnesota 56537
Fosston, Minnesota 56542
Fridley, Minnesota 55432
Hibbing, Minnesota 55746
Maple Grove, Minnesota 55369
Maplewood, Minnesota 55109
Maplewood, Minnesota 55109
Minneapolis, Minnesota 55407
Minneapolis, Minnesota 55415
Minneapolis, Minnesota 55454
Monticello, Minnesota 55362
New Ulm, Minnesota 56073
Park Rapids, Minnesota 56470
Princeton, Minnesota 55371
Robbinsdale, Minnesota 55422
Saint Louis Park, Minnesota 55416
Saint Paul, Minnesota 55101
Saint Paul, Minnesota 55102
Sandstone, Minnesota 55072
Shakopee, Minnesota 55379
Stillwater, Minnesota 55082
Thief River Falls, Minnesota 56701
Site Public Contact
605-312-3320
Virginia, Minnesota 55792
Waconia, Minnesota 55387
Willmar, Minnesota 56201
Woodbury, Minnesota 55125
Worthington, Minnesota 56187
Site Public Contact
605-312-3320
Wyoming, Minnesota 55092
Columbus, Mississippi 39705
Grenada, Mississippi 38901
Hattiesburg, Mississippi 39401
Hattiesburg, Mississippi 39404
Jackson, Mississippi 39216
Site Public Contact
601-815-6700
New Albany, Mississippi 38652
Oxford, Mississippi 38655
Southhaven, Mississippi 38671
Ballwin, Missouri 63011
Site Public Contact
314-251-7058
Bonne Terre, Missouri 63628
Site Public Contact
314-996-5569
Branson, Missouri 65616
Site Public Contact
417-269-4520
Cape Girardeau, Missouri 63703
Cape Girardeau, Missouri 63703
Site Public Contact
573-651-5550
Chesterfield, Missouri 63017
Site Public Contact
314-205-6936
Creve Coeur, Missouri 63141
Jefferson City, Missouri 65109
Joplin, Missouri 64804
Joplin, Missouri 64804
Kansas City, Missouri 64108
Site Public Contact
816-404-4375
Kansas City, Missouri 64128
Site Public Contact
800-525-1483
Kansas City, Missouri 64131
Kansas City, Missouri 64154
Lee's Summit, Missouri 64064
Rolla, Missouri 65401
Rolla, Missouri 65401
Saint Joseph, Missouri 64507
Saint Louis, Missouri 63109
Site Public Contact
314-353-1870
Saint Louis, Missouri 63110
Saint Louis, Missouri 63129
Saint Louis, Missouri 63131
Site Public Contact
314-996-5569
Saint Louis, Missouri 63136
Saint Louis, Missouri 63141
Site Public Contact
314-251-7066
Saint Peters, Missouri 63376
Sainte Genevieve, Missouri 63670
Site Public Contact
314-996-5569
Springfield, Missouri 65804
Site Public Contact
417-269-4520
Springfield, Missouri 65807
Site Public Contact
417-269-4520
Sullivan, Missouri 63080
Site Public Contact
314-996-5569
Sunset Hills, Missouri 63127
Site Public Contact
314-996-5569
Washington, Missouri 63090
Site Public Contact
636-390-1600
Anaconda, Montana 59711
Billings, Montana 59101
Billings, Montana 59101
Billings, Montana 59102
Site Public Contact
800-648-6274
Bozeman, Montana 59715
Butte, Montana 59701
Site Public Contact
406-723-2621
Great Falls, Montana 59405
Great Falls, Montana 59405
Helena, Montana 59601
Kalispell, Montana 59901
Missoula, Montana 59804
Grand Island, Nebraska 68803
Kearney, Nebraska 68847
Lincoln, Nebraska 68510
Omaha, Nebraska 68114
Site Public Contact
402-354-5144
Omaha, Nebraska 68122
Omaha, Nebraska 68124
Omaha, Nebraska 68130
Omaha, Nebraska 68131
Papillion, Nebraska 68046
Carson City, Nevada 89703
Henderson, Nevada 89052
Henderson, Nevada 89052
Henderson, Nevada 89052
Henderson, Nevada 89052
Henderson, Nevada 89052
Henderson, Nevada 89074
Henderson, Nevada 89074
Las Vegas, Nevada 89102
Las Vegas, Nevada 89102
Las Vegas, Nevada 89103
Las Vegas, Nevada 89106
Las Vegas, Nevada 89106
Las Vegas, Nevada 89106
Las Vegas, Nevada 89109
Las Vegas, Nevada 89109
Las Vegas, Nevada 89109
Las Vegas, Nevada 89113
Las Vegas, Nevada 89119
Las Vegas, Nevada 89128
Las Vegas, Nevada 89128
Las Vegas, Nevada 89128
Las Vegas, Nevada 89128
Las Vegas, Nevada 89128
Las Vegas, Nevada 89128
Las Vegas, Nevada 89128
Las Vegas, Nevada 89128
Las Vegas, Nevada 89135
Las Vegas, Nevada 89144
Las Vegas, Nevada 89144
Las Vegas, Nevada 89144
Las Vegas, Nevada 89148-2405
Las Vegas, Nevada 89148
Las Vegas, Nevada 89148
Las Vegas, Nevada 89148
Las Vegas, Nevada 89149
Las Vegas, Nevada 89169
Las Vegas, Nevada 89169
Pahrump, Nevada 89048
Reno, Nevada 89502
Reno, Nevada 89503
Reno, Nevada 89509
Lebanon, New Hampshire 03756
Manchester, New Hampshire 03102
Site Public Contact
603-629-1828
Nashua, New Hampshire 03063
Morristown, New Jersey 07960
Site Public Contact
973-971-5900
Pompton, New Jersey 07444
Summit, New Jersey 07902
Site Public Contact
908-522-2043
Vineland, New Jersey 08360
Site Public Contact
856-641-7933
Albuquerque, New Mexico 87102
Albuquerque, New Mexico 87102
Albuquerque, New Mexico 87109
Albuquerque, New Mexico 87110
Las Cruces, New Mexico 88011
Rio Rancho, New Mexico 87124
Buffalo, New York 14263
Glens Falls, New York 12801
Site Public Contact
518-926-6700
New York, New York 10016
Rochester, New York 14642
Site Public Contact
585-275-5830
Stony Brook, New York 11794
Site Public Contact
800-862-2215
Asheville, North Carolina 28803
Clinton, North Carolina 28328
Goldsboro, North Carolina 27534
Goldsboro, North Carolina 27534
Hendersonville, North Carolina 28791
Hendersonville, North Carolina 28792
Jacksonville, North Carolina 28546
Jacksonville, North Carolina 28546
Bismarck, North Dakota 58501
Fargo, North Dakota 58103
Fargo, North Dakota 58103
Site Public Contact
701-234-6161
Fargo, North Dakota 58122
Fargo, North Dakota 58122
Jamestown, North Dakota 58401
Beavercreek, Ohio 45431
Belpre, Ohio 45714
Boardman, Ohio 44512
Canton, Ohio 44708
Site Public Contact
888-293-4673
Centerville, Ohio 45459
Centerville, Ohio 45459
Chillicothe, Ohio 45601
Cincinnati, Ohio 45220
Cincinnati, Ohio 45236
Cincinnati, Ohio 45242
Cincinnati, Ohio 45247
Cincinnati, Ohio 45255
Cleveland, Ohio 44109
Cleveland, Ohio 44195
Columbus, Ohio 43210
Columbus, Ohio 43213
Columbus, Ohio 43214
Columbus, Ohio 43214
Columbus, Ohio 43215
Columbus, Ohio 43219
Columbus, Ohio 43222
Columbus, Ohio 43228
Dayton, Ohio 45406
Dayton, Ohio 45409
Dayton, Ohio 45415
Dayton, Ohio 45415
Delaware, Ohio 43015
Delaware, Ohio 43015
Dublin, Ohio 43016
Findlay, Ohio 45840
Findlay, Ohio 45840
Franklin, Ohio 45005-1066
Franklin, Ohio 45005
Greenville, Ohio 45331
Kettering, Ohio 45409
Kettering, Ohio 45420
Kettering, Ohio 45429
Lancaster, Ohio 43130
Mansfield, Ohio 44903
Marietta, Ohio 45750
Marion, Ohio 43302
Mount Vernon, Ohio 43050
Newark, Ohio 43055
Newark, Ohio 43055
Perrysburg, Ohio 43551
Portsmouth, Ohio 45662
Sandusky, Ohio 44870
Springfield, Ohio 45504
Springfield, Ohio 45505
Sylvania, Ohio 43560
Site Public Contact
419-824-1842
Toledo, Ohio 43606
Site Public Contact
419-824-1842
Toledo, Ohio 43623
Site Public Contact
419-407-1160
Toledo, Ohio 43623
Site Public Contact
800-444-3561
Troy, Ohio 45373
Troy, Ohio 45373
Warren, Ohio 44484
Westerville, Ohio 43081
Youngstown, Ohio 44501
Zanesville, Ohio 43701
Lawton, Oklahoma 73505
Site Public Contact
877-231-4440
Oklahoma City, Oklahoma 73104
Oklahoma City, Oklahoma 73120
Site Public Contact
405-752-3402
Baker City, Oregon 97814
Bend, Oregon 97701
Clackamas, Oregon 97015
Clackamas, Oregon 97015
Coos Bay, Oregon 97420
Gresham, Oregon 97030
Site Public Contact
503-413-2150
Newberg, Oregon 97132
Ontario, Oregon 97914
Portland, Oregon 97210
Portland, Oregon 97213
Portland, Oregon 97225
Portland, Oregon 97227
Portland, Oregon 97239
Redmond, Oregon 97756
Site Public Contact
541-706-2909
Tualatin, Oregon 97062
Site Public Contact
503-413-1742
Allentown, Pennsylvania 18103
Bethlehem, Pennsylvania 18017
Chadds Ford, Pennsylvania 19317
Doylestown, Pennsylvania 18901
East Stroudsburg, Pennsylvania 18301
Erie, Pennsylvania 16544
Site Public Contact
814-452-5000
Hazleton, Pennsylvania 18201
Site Public Contact
570-501-1242
Jefferson Hills, Pennsylvania 15025
Monroeville, Pennsylvania 15146
Site Public Contact
412-858-7746
Philadelphia, Pennsylvania 19107
Philadelphia, Pennsylvania 19140
Site Public Contact
215-728-2983
Pittsburgh, Pennsylvania 15212
Site Public Contact
877-284-2000
Pittsburgh, Pennsylvania 15224
Site Public Contact
412-578-5000
Pittsburgh, Pennsylvania 15232
Site Public Contact
412-647-8073
Pottstown, Pennsylvania 19464
Site Public Contact
610-327-7544
Wexford, Pennsylvania 15090
Charleston, South Carolina 29425
Clinton, South Carolina 29325
Easley, South Carolina 29640
Gaffney, South Carolina 29341
Georgetown, South Carolina 29440
Greenville, South Carolina 29601
Greenville, South Carolina 29605
Greenville, South Carolina 29605
Greenville, South Carolina 29605
Greenville, South Carolina 29607
Greenville, South Carolina 29615
Greer, South Carolina 29650
Greer, South Carolina 29651
Seneca, South Carolina 29672
Spartanburg, South Carolina 29303
Spartanburg, South Carolina 29307
Union, South Carolina 29379
Sioux Falls, South Dakota 57104
Sioux Falls, South Dakota 57117-5134
Collierville, Tennessee 38017
Franklin, Tennessee 37067
Site Public Contact
800-811-8480
Memphis, Tennessee 38120
Nashville, Tennessee 37204
Site Public Contact
800-811-8480
Nashville, Tennessee 37232
Site Public Contact
800-811-8480
Bryan, Texas 77802
Dallas, Texas 75235
Dallas, Texas 75390
Fort Worth, Texas 76104
Houston, Texas 77026-1967
Site Public Contact
713-566-5000
Houston, Texas 77030
San Antonio, Texas 78229
American Fork, Utah 84003
Cedar City, Utah 84720
Farmington, Utah 84025
Logan, Utah 84321
Murray, Utah 84107
Ogden, Utah 84403
Provo, Utah 84604
Riverton, Utah 84065
Saint George, Utah 84770
Salt Lake City, Utah 84106
Salt Lake City, Utah 84112
Salt Lake City, Utah 84143
South Jordan, Utah 84009
Berlin, Vermont 05602
Site Public Contact
802-225-5400
Burlington, Vermont 05401
Burlington, Vermont 05405
Richmond, Virginia 23298
Aberdeen, Washington 98520
Auburn, Washington 98001
Bainbridge Island, Washington 98110
Bellevue, Washington 98004
Bellingham, Washington 98225
Bremerton, Washington 98310
Bremerton, Washington 98310
Burien, Washington 98166
Centralia, Washington 98531
Edmonds, Washington 98026
Enumclaw, Washington 98022
Everett, Washington 98201
Federal Way, Washington 98002
Federal Way, Washington 98003
Gig Harbor, Washington 98332
Gig Harbor, Washington 98335
Issaquah, Washington 98029
Kennewick, Washington 99336
Kennewick, Washington 99336
Lacey, Washington 98503
Lakewood, Washington 98499
Longview, Washington 98632
Lynnwood, Washington 98036
Mount Vernon, Washington 98274
Mount Vernon, Washington 98274
Port Townsend, Washington 98368
Site Public Contact
360-344-3091
Poulsbo, Washington 98370
Puyallup, Washington 98372
Puyallup, Washington 98372
Renton, Washington 98055
Seattle, Washington 98101
Seattle, Washington 98104
Seattle, Washington 98107
Seattle, Washington 98109
Site Public Contact
800-804-8824
Seattle, Washington 98109
Site Public Contact
800-804-8824
Seattle, Washington 98122-4307
Seattle, Washington 98195
Site Public Contact
800-804-8824
Sedro-Woolley, Washington 98284
Site Public Contact
360-788-8240
Shelton, Washington 98584
Spokane Valley, Washington 99216
Spokane, Washington 99204
Spokane, Washington 99208
Spokane, Washington 99216
Spokane, Washington 99218
Tacoma, Washington 97405
Tacoma, Washington 98405
Tacoma, Washington 98405
Tacoma, Washington 98405
Vancouver, Washington 98664
Vancouver, Washington 98684
Vancouver, Washington 98686
Site Public Contact
503-413-2150
Walla Walla, Washington 99362
Wenatchee, Washington 98801
Site Public Contact
509-665-5800
Yakima, Washington 98902
Yelm, Washington 98597
Huntington, West Virginia 25701
Site Public Contact
304-399-6617
Ashland, Wisconsin 54806
Ashland, Wisconsin 54806
Chippewa Falls, Wisconsin 54729
Eau Claire, Wisconsin 54701
Green Bay, Wisconsin 54301
Green Bay, Wisconsin 54303
La Crosse, Wisconsin 54601
Ladysmith, Wisconsin 54848
Manitowoc, Wisconsin 54221
Site Public Contact
920-320-2749
Marinette, Wisconsin 54143
Marshfield, Wisconsin 54449
Minocqua, Wisconsin 54548
New Richmond, Wisconsin 54017
Oconto Falls, Wisconsin 54154
Rice Lake, Wisconsin 54868
Sheboygan, Wisconsin 53081
Stevens Point, Wisconsin 54482
Sturgeon Bay, Wisconsin 54235-1495
Wausau, Wisconsin 54401
Weston, Wisconsin 54476
Wisconsin Rapids, Wisconsin 54494
Cheyenne, Wyoming 82001
Cody, Wyoming 82414
Sheridan, Wyoming 82801
More Details
- NCT ID
- NCT02834013
- Status
- Recruiting
- Sponsor
- National Cancer Institute (NCI)
Detailed Description
PRIMARY OBJECTIVES:
I. To evaluate the Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 overall response rate (ORR) in subsets of patients with advanced rare cancers treated with ipilimumab plus nivolumab combination immunotherapy.
II. To evaluate the overall response rate (ORR) in patients with gestational trophoblastic tumors treated with ipilimumab plus nivolumab combination immunotherapy.
III. To evaluate the RECIST v1.1 overall response rate (ORR) in patients PD-L1 amplified cancers treated with nivolumab immunotherapy.
SECONDARY OBJECTIVES:
I. To evaluate toxicities in each cohort. II. To estimate overall survival (OS), progression-free survival (PFS), clinical benefit rate; and to estimate immune related (i)RECIST ORR (iORR), and iRECIST PFS (iPFS) across cohorts and within each cohort.
TRANSLATIONAL MEDICINE OBJECTIVES:
I. Across strata, to evaluate the association of tumor mutational burden measured by tissue sequencing with durable response (complete response [CR] or partial response [PR] lasting 24 weeks or more).
II. Within strata, to describe the mutational load and targeted sequencing of well-known oncogenes and changes in these markers of patients at up to three time points (baseline, cycle 2, and progression), and across strata to describe associations with survival outcomes.
III. Within strata, to describe the presence of germline mutations, and across strata to evaluate association with outcome.
IV. Within strata, to describe patient risk category as defined by the biodesix protein signature and change over time at up to three time points (baseline, cycle 2, progression), and across strata to evaluate associations with outcomes.
V. Across strata, to evaluate the association of PD-L1 expression (positive versus negative) with response and survival outcomes, and within strata, to characterize baseline PD-L1 prevalence.
VI. To collect specimens for banking for use in future correlative biomarker research studies.
OUTLINE: Patients are assigned to 1 of 2 arms.
ARM I (ALL COHORTS EXCEPT THE PD-L1 AMPLIFIED COHORT): Patients receive nivolumab intravenously (IV) over 30 minutes on days 1, 15, and 29 and ipilimumab IV over 60 minutes on day 1. Cycles repeat every 42 days in the absence of disease progression or unacceptable toxicity.
ARM II (PD-L1 AMPLIFIED COHORT): Patients receive nivolumab IV over 30 minutes on days 1, 15 and 29. Cycles repeat every 42 days in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up for 10 years from registration.